Freestone Grove Partners LP Regeneron Pharmaceuticals, Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 64,229 shares of REGN stock, worth $44.5 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
64,229
Previous 43,411
47.96%
Holding current value
$44.5 Million
Previous $22.8 Billion
58.46%
% of portfolio
0.27%
Previous 0.17%
Shares
2 transactions
Others Institutions Holding REGN
# of Institutions
1,476Shares Held
86.5MCall Options Held
2.38MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA9.05MShares$6.27 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.86 Billion0.2% of portfolio
-
State Street Corp Boston, MA4.69MShares$3.25 Billion0.09% of portfolio
-
Dodge & Cox San Francisco, CA4.55MShares$3.16 Billion1.47% of portfolio
-
Jpmorgan Chase & CO New York, NY4.07MShares$2.82 Billion0.15% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...